OssDsign AB (publ)

DB:5J6 Stock Report

Market Cap: €70.8m

OssDsign Valuation

Is 5J6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5J6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 5J6's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 5J6's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5J6?

Key metric: As 5J6 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 5J6. This is calculated by dividing 5J6's market cap by their current revenue.
What is 5J6's PS Ratio?
PS Ratio6.4x
SalesSEK 127.49m
Market CapSEK 815.45m

Price to Sales Ratio vs Peers

How does 5J6's PS Ratio compare to its peers?

The above table shows the PS ratio for 5J6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
PHH2 Paul Hartmann
0.3xn/a€745.9m
V3V VITA 34
0.9x2.9%€72.2m
LIK LIMES Schlosskliniken
2.3x17.7%€96.2m
PUS PULSION Medical Systems
3.8xn/a€134.4m
5J6 OssDsign
6.4x24.9%€815.5m

Price-To-Sales vs Peers: 5J6 is expensive based on its Price-To-Sales Ratio (6.4x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does 5J6's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
5J6 6.4xIndustry Avg. 3.7xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 5J6 is expensive based on its Price-To-Sales Ratio (6.4x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 5J6's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5J6 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.4x
Fair PS Ratio4.8x

Price-To-Sales vs Fair Ratio: 5J6 is expensive based on its Price-To-Sales Ratio (6.4x) compared to the estimated Fair Price-To-Sales Ratio (4.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5J6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.70
€1.04
+48.0%
6.8%€1.12€0.95n/a3
Nov ’25€0.53
€1.09
+106.0%
10.1%€1.23€0.97n/a3
Oct ’25€0.56
€1.09
+95.7%
10.1%€1.23€0.97n/a3
Sep ’25€0.61
€1.09
+78.6%
10.1%€1.23€0.97n/a3
Aug ’25€0.77
€1.15
+49.5%
15.3%€1.40€1.01n/a3
Jul ’25€0.79
€1.13
+43.6%
15.3%€1.38€0.99n/a3
Jun ’25€0.83
€1.13
+37.3%
15.3%€1.38€0.99n/a3
May ’25€0.79
€1.14
+44.1%
14.5%€1.37€0.98n/a3
Apr ’25€0.84
€1.22
+45.4%
15.1%€1.42€0.97n/a4
Mar ’25€0.75
€1.22
+62.4%
15.1%€1.42€0.97n/a4
Feb ’25€0.75
€1.20
+61.4%
13.1%€1.37€0.97n/a4
Jan ’25€0.67
€1.29
+90.7%
5.8%€1.36€1.18n/a3
Dec ’24€0.61
€1.29
+111.4%
5.8%€1.36€1.18n/a3
Nov ’24€0.45
€1.26
+181.1%
12.3%€1.39€1.04€0.533
Oct ’24€0.52
€1.26
+142.6%
12.3%€1.39€1.04€0.563
Sep ’24€0.43
€1.11
+160.1%
14.0%€1.30€0.93€0.613
Aug ’24€0.47
€1.13
+139.5%
17.0%€1.40€0.99€0.773
Jul ’24€0.40
€1.13
+185.4%
17.0%€1.40€0.99€0.793
Jun ’24€0.38
€1.13
+197.4%
17.0%€1.40€0.99€0.833
May ’24€0.39
€1.13
+192.1%
17.0%€1.40€0.99€0.793
Apr ’24€0.39
€1.13
+188.3%
17.0%€1.40€0.99€0.843
Mar ’24€0.43
€1.13
+161.9%
17.0%€1.40€0.99€0.753
Feb ’24€0.47
€1.17
+147.5%
25.4%€1.43€0.75€0.753
Jan ’24€0.49
€1.17
+137.2%
25.4%€1.43€0.75€0.673
Dec ’23€0.42
€1.17
+176.4%
25.4%€1.43€0.75€0.613
Nov ’23€0.36
€1.24
+245.2%
19.9%€1.47€0.90€0.453

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%